Company Announcement - Glucotrack, Inc announced the appointment of Ted Williams as Vice President of Regulatory Affairs, effective immediately [1] - Ted Williams brings nearly 25 years of experience in Regulatory Affairs and Quality Assurance for Class III medical devices, including implantable continuous glucose monitors (CGM) and drug/device combination products [2] - Williams previously served as Vice President of Regulatory Affairs/Quality Assurance at Glysens Inc, a company focused on developing implantable CGM technology [2] Product Development - Glucotrack is developing a long-term implantable continuous blood glucose monitoring system (CBGM) with a sensor longevity of 3 years and minimal calibration requirements [3] - The CBGM system does not require an on-body wearable component, distinguishing it from other CGM technologies [3] - The company is advancing human clinical trials and creating a strategic regulatory program for the CBGM [8] Leadership Perspective - Paul V Goode, PhD, President and CEO of Glucotrack, emphasized that Williams' expertise in regulatory pathways will be instrumental in progressing the CBGM through FDA approval and beyond [4] - Williams expressed honor in joining Glucotrack at a pivotal time as the company advances its clinical trials and regulatory strategy for the CBGM [8] Company Overview - Glucotrack, Inc is a medical technology company focused on designing, developing, and commercializing novel technologies for people with diabetes [7] - The company's primary focus is on developing a long-term implantable continuous blood glucose monitoring system for diabetes patients [7]
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs